Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
MedPacto trials revive deal prospects as Theragen Etex weighs holding stake
12+ hour, 39+ min ago (13+ words) CHOSUNBIZ Chosunbiz...
Germantown???s Seraxis Announces Merger to Form Diabetes-Focused Biotech Company
15+ hour, 38+ min ago (339+ words) Announced September 8, the merger is expected to close in November 2026, subject to shareholder approval. The combined company will be headquartered in Germantown, with integrated research laboratories and manufacturing capabilities. Seraxis, a private biotechnology company launched in 2013, is located at 20400 Century…...
Cancer Drug Hand-Foot Syndrome Risks Mapped in Huge FDA Analysis
12+ hour, 42+ min ago (55+ words) A painful, red, blistering rash on the palms and soles is one of the most common reasons cancer patients quietly suffer through their treatment, and a new analysis of more than two decades of American drug-safety reports is now offering…...
From Pet X-Rays to Human ECGs: The Unusual Road SL Labs Is Taking
15+ hour, 15+ min ago (1646+ words) What veterinary AI, wearable ECGs, and a blockchain credit economy have in common — and why SL Labs may be taking a less obvious route into healthcare. There is something slightly unusual about the way SL Labs is building its healthcare…...
Antibody-Drug Conjugate Hits Recommended Phase 3 Dose in EGFR-Mutated Lung
19+ hour, 26+ min ago (832+ words) An investigational antibody-drug conjugate that simultaneously targets two of the most important growth-driving proteins in lung cancer has delivered encouraging clinical results in patients whose tumors had already resisted modern targeted therapy, according to data presented at the International Association…...
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
2+ day, 2+ min ago (321+ words) Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million....
Breast cancer pill from AstraZeneca misses mark in pivotal trial
1+ day, 6+ hour ago (204+ words) STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories…...
Biotech Startups Qualify for R&D Tax Credits More Often Than They Realize, K-38 Consulting Reports
1+ day, 12+ hour ago (86+ words) ...
Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics
2+ week, 5+ day ago (200+ words) Aug 24, 2026 6:57pm EDT GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. (“Clywedog”) in an all-stock transaction. Notice of Delisting…...
AI-enabled clinical trials
1+ day, 7+ hour ago (1349+ words) {“title”:”AI-Enabled Clinical Trials Are Poised to Transform How New Medicines Are Tested”,”html”:”Clinical trials have long been the slowest, most expensive and most unpredictable stage of medical research. A promising molecule identified in the laboratory can take a…...